Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid Tumors

Eric Whitman, MD
Published: Friday, May 17, 2019



Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in nonimmunogenic solid tumors.

At Morristown Medical Center’s 7th Annual Joseph Calello Melanoma Scholar presentation, Adil Daud, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discussed ways to turn “cold” tumors into “hot” tumors. Atlantic Health System is conducting several trials looking at the role of interleukin (IL)-12 in increasing the immunogenicity of a tumor. In these trials, patients who have failed multiple lines of therapy are treated with anti–PD-1 agents and IL-12 via electroporation.

Other ongoing work is assessing T cell response to immunotherapy. In the cases of “cold” tumors, researchers believe the T cells become exhausted and are unable to generate an immune response. If researchers can use IL-12 to reactivate the T cells remains to be seen, Whitman concludes.
SELECTED
LANGUAGE


Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in nonimmunogenic solid tumors.

At Morristown Medical Center’s 7th Annual Joseph Calello Melanoma Scholar presentation, Adil Daud, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discussed ways to turn “cold” tumors into “hot” tumors. Atlantic Health System is conducting several trials looking at the role of interleukin (IL)-12 in increasing the immunogenicity of a tumor. In these trials, patients who have failed multiple lines of therapy are treated with anti–PD-1 agents and IL-12 via electroporation.

Other ongoing work is assessing T cell response to immunotherapy. In the cases of “cold” tumors, researchers believe the T cells become exhausted and are unable to generate an immune response. If researchers can use IL-12 to reactivate the T cells remains to be seen, Whitman concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x